The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $10. Insiders have been net sellers over the past quarter.
Genius Sports Limited
GENI · the NYSE · USD · Market cap $1.8B · 2,000 employees
Genius Sports Limited provides technology-led products and services to the sports, sports betting, and sports media industries in the Americas, Europe, and internationally.
PASS · Titan Ethical · score 70.0Price as of 28 Oct 2026Daily close, not a live quote
Screened 2026-10-28 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price6.35 USD at the 28 Oct 2026 close
- Ethical screenPasses, score 70.0 out of 100
- OptionsOpen interest leans heavily to calls (put/call 0.09)
- Last reviewed28 Oct 2026 (1 days ago)
A summary of the dated readings below, not a live quote and not advice.
What this means: price 6.35 against the desk's fair-value range, base estimate 12.70, over the last year.
- Trend Accumulation
- Insiders insiders sold, $5,255,568, latest filing 2026-09-15
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.09, read 2026-10-22
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Genius Sports Limited holds its Accumulation at $6.35. The statistical read favours the sellers, held for 90 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 90 days |
| Price at the screen | $6.35 |
| Valuation | N/A trailing · 6.11 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 1.91 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 2.70% | Below 33% | Interest-bearing debt is just 2.7% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 0.00% | Below 33% | Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit. | Pass |
| Receivables | 36.35% | Below 49% | Money owed to the company is 36.4% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.18% | Below 5% | Only 0.2% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Genius Sports clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 3%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when GENI's ethical verdict changes
Today GENI passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. A 100.0% margin of safety to the base estimate.
Third-party analyst targets: 21 covering, consensus Strong Buy. The average target sits +65% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsSports betting data still needs a profitable collector
Every time a goal is scored or an odds line moves, the raw data has to be captured, cleaned and sold in milliseconds. Genius Sports sits in that pipe, supplying the infrastructure that bookmakers and broadcasters rely on across Europe and the Americas. Revenue is expanding at 30 percent, the forward multiple sits at just 6.5 times and the ethical screen is clear.
Yet the numbers still do not add up. Profit margins remain negative at minus 22 percent and return on equity is minus 23 percent, so the low multiple reflects losses rather than a bargain. With an opportunity rating of none we stay on the side-lines even though analysts see upside to ten dollars and our own fair value sits higher.
Currency swings, customer concentration and the race to stay ahead of bigger data rivals keep execution risk elevated. Until cash generation turns consistently positive the valuation gap is more trap than opportunity.
Analysis, not advice.
| Forward P/E | 6.1xcheap for a company growing this fast |
| EPS, trailing | -0.67 |
| EPS, forward | 1.07 |
| Revenue growth | +64.7%growing very fast |
| Profit margin | -23.0%currently unprofitable |
| Return on equity | -25.9%not currently earning a positive return on equity |
| FCF yield | 9.19% |
| Debt to equity | 1.20a meaningful debt load worth watching |
| Current ratio | 0.97below 1: short-term bills exceed liquid assets |
| Beta | 1.91much more volatile than the market |
| Short interest, float | 0.16% |
| 52-week range | 3.83 - 12.17 |
| Market cap | $1.8B |
| Employees | 2,000 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeGENI trades on the NYSE (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $10. Insiders have been net sellers over the past quarter.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $10. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 27.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $10. Insiders have been net sellers over the past quarter.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 26.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $10.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 8.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $10.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 27%. Our forward projection puts the odds of a 10% gain over the next month near 29%. The street (18 analysts) rates it strong buy, with a mean price target of $10.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Genius Sports CEO Mark Locke on Prediction Markets and the Data Behind the Game Yahoo Finance · 13d ago
- Genius Sports Connects Official, Real-Time NFL Data to NFL Gametime on X Yahoo Finance · 14d ago
- Genius Sports Outlook Supported by Legend Synergies, Data Demand, Oppenheimer Says Yahoo Finance · 15d ago
- Stocktwits Retail Therapy: Consumer Stocks Snap Losing Streaks As Planet Fitness, MercadoLibre And Genius Sports Rally Yahoo Finance · 17d ago
- Snorkel AI Raises $350 Million to Help Push the Frontier: NYSE Content Update Yahoo Finance · 22d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-15 | Locke Mark | CEO | S - Sale+OE | 800,000 | $5,255,568 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-08-05 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-08-05 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-08-05 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-08-05 | Ro Khanna | Democrat | sell | 1K–15K |
| 2026-08-05 | Ro Khanna | Democrat | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $4.41 | +54.4% | · | $1,544 | +54.4% |
| 2 months | $3.92 | +73.7% | · | $1,737 | +73.7% |
| 3 months | $5.17 | +31.7% | · | $1,317 | +31.7% |
| 6 months | $11.06 | -38.4% | · | $616 | -38.4% |
| 1 year | $9.38 | -27.4% | · | $726 | -27.4% |
| 2 years | $5.32 | +28.0% | · | $1,280 | +28.0% |
| 3 years | $5.85 | +16.4% | · | $1,164 | +16.4% |
| 5 years | $18.93 | -64.0% | · | $360 | -64.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever GENI does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.